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E D I T O R I A L
The International Consortium Investigating Neurocognition in 
Bipolar Disorder (ICONIC‐BD)
Bipolar disorder (BD) is the fourth leading cause of disability world‐
wide among young people of age range 10‐24 years. Although the 
diagnosis is largely defined by the mood episodes associated with 
the illness, cognitive deficits are among the most persistent and dis‐
abling symptoms of illness and have a profound impact on clinical 
course and functional outcome. Specifically, trait‐like impairment is 
common in the domains of attention, verbal learning, and executive 
function; these deficits contribute to functional disability and are 
targets for emerging treatments and preventions. Although consid‐
erable progress has been made over the past two decades, our un‐
derstanding of the underlying causes of the cognitive deficits in BD 
remains surprisingly limited. As such, there are no approved treat‐
ments for this disabling symptom specific to BD.1
Clinicians who treat patients with BD can attest to the vast range 
of functioning seen within BD, with some individuals achieving high‐
level occupational and social status while others are broadly disabled 
for most of their lives.2 Research has shown that at the group level, 
cognitive deficits are present in euthymic BD patients, and are qual‐
itatively similar to those seen in schizophrenia (SZ), albeit consis‐
tently less severe; however, group‐level comparisons inherently fail 
to take into account heterogeneity in cognitive profiles within the 
disorder. In stark contrast to the very high rates of cognitive defi‐
cits in SZ, data suggest that approximately 30%‐50% of BD patients 
present as “neuropsychologically normal” (not different from age‐
matched non‐psychiatric controls) during periods of euthymia.3 We 
cannot yet answer the critical question of why some patients with 
BD develop significant cognitive deficits while others appear rela‐
tively resilient to cognitive decline and maintain high levels of social 
and occupational functioning. Large‐scale studies are needed to better 
identify both risk and resilience factors for cognitive impairment in BD.
What diagnostic and clinical factors account for cognitive and func‐
tional heterogeneity in BD? Several clinical factors have been associ‐
ated with cognitive impairment in BD, including bipolar subtype (BD I 
vs BD II); however, considerable discrepancy is notable across studies, 
and recent meta‐analyses suggest that between‐group differences 
are very subtle.4 Previously reported subgroup differences may be—
at least in part—due to the greater frequency of psychosis in BD I vs 
BD II, but individual studies have thus far been underpowered to test 
these types of fine‐grained hypotheses. Beyond diagnostic heteroge‐
neity, the course of the illness varies considerably among BD patients 
and is thought to contribute to cognitive and functional outcomes. 
Meta‐analytic (cross‐sectional) data suggest that a longer duration of 
illness, higher number of prior mood episodes, and history of psychosis 
are associated with more pronounced cognitive impairment indica‐
tive of a neuroprogressive course; however, each individual study has 
been small and thereby unable to address specific questions such as 
whether the polarity of prior episodes, duration of illness, or medica‐
tion effects are relevant to cognitive outcome. Interestingly, very few 
studies have adequately addressed one of the most basic questions 
in BD—how does current symptom severity affect the nature and ex‐
tent of cognitive impairment and is this a bidirectional effect? Many 
other illness‐related factors are likely to contribute to cognitive and 
functional outcomes in BD (eg, sleep, obesity, comorbid medical and 
psychiatric conditions, among others); however, these are relatively 
understudied and sample sizes are modest.
In an effort to advance the field through collaboration and open 
data sharing, we have initiated the first international consortium fo‐
cused on this highly significant topic: The International Consortium 
Investigating Cognition in Bipolar Disorder (ICONIC‐BD). This effort 
brings together a large, international team of experts in BD with 
existing data on cognition in individuals with BD to form a unique 
consortium with the ability to unambiguously address some of these 
important questions through large‐scale mega‐analyses.
The idea for this project stemmed from the International Society 
for Bipolar Disorder (ISBD) Targeting Cognition Task Force meeting held 
in Mexico City in March 2018. All task force members were initially 
invited to contribute data to the consortium. Each investigator who 
had data to contribute enthusiastically agreed to do so—indicating a 
strong collaborative network.
We have assembled a strong team of investigators from across 
the world to form ICONIC‐BD; however, to optimize the impact that 
this consortium will have, global outreach is necessary. We hope to 
identify other investigators via PubMed searches and word of mouth 
who have existing cognitive data in BD patients and invite them to 
join us. This will be open to any investigator with data to contribute 
who is interested in participating.
The coordinating site for ICONIC‐BD is the Brigham and Women's 
Hospital (BWH); Harvard Medical School in Boston, Massachusetts, 
USA, led by Katherine Burdick. She is joined by co‐leaders Kamilla 
Miskowiak (University of Copenhagen); Eduard Vieta (University 
of Barcelona); and Lakshmi Yatham (University of British Columbia) 
forming a 4‐member executive committee who will oversee the ef‐
fort. To date, we have already enlisted participation from a total of 
15 sites who have provided meta‐data for inclusion in this initiative 
(Table 1). Estimated sample sizes (as of 12/2018) are >3000 BD indi‐
viduals and >2000 healthy controls.
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After evaluating the nature of the existing data, we have begun 
the development of a single platform (eg, define variables of inter‐
est from each measure, provide uniform labels) into which each site 
will place their data for transfer to BWH and upon which the master 
database will be built. As different neurocognitive batteries were 
used across sites, data harmonization will be critical to optimize the 
utility of the merged dataset. Quality control methods will be imple‐
mented to handle missing values to optimize available information 
while maintaining data integrity; data will be examined for normality 
and transformed as necessary; and all test scores will be converted 
to standard scales based upon the healthy control normative sample 
(eg, z‐scores with mean of zero and standard deviation of one).
Preliminary analyses will be conducted to define primary out‐
come measures at three levels. Global outcomes will be calculated 
using principal components analyses (PCA) to derive a general cog‐
nitive ability “g” score. This will be done in a standard manner where 
g is defined as the first factor from an unrotated PCA, which will 
be conducted separately as each site using the maximum number 
of tests available (but at least three tests) to calculate g. The global 
measure g has distinct advantages in consortium analyses, as it al‐
lows all cases (with at least three cognitive measures) to be included 
in analyses, regardless of the different batteries used at each site. 
This is based on data that show that when large samples have been 
tested on different cognitive test batteries, the derived general cog‐
nitive factors (g) correlate very highly with one another (approaching 
r = 1.0); that is, g factors derived from different groups of tests rank 
people almost identically.5 An additional advantage of this measure 
is that it captures a large percentage of the variance on other cog‐
nitive domains/tests and, as such, it is predictive of many import‐
ant functional outcomes. The relative disadvantage is that g may 
not capture some of the more nuanced aspects of neurocognitive 
functioning that are impaired in BD or the cognitive heterogeneity 
that exists. As such, the second level of analyses will focus on do‐
main‐level outcomes, which will be defined based upon results from 
the PCA as well as calculating mean z‐scores across similar pre‐de‐
termined tasks. Finally, test‐level outcomes will be selected based 
upon the most representative (and available) variables for each in‐
dividual task.
Data from other measures that are related to cognitive outcome 
in BD will also need to be summarized and merged into the database. 
This will include demographic information and several illness‐related 
scales. Data from standardized mood ratings are available from each 
site; however, not all sites use the same scales (eg, Montgomery 
Asberg [MADRS] vs Hamilton [HamD] depression rating scales). As 
such, severity of mood symptoms at the time of assessment will be 
converted to a common metric to be used in analyses. Illness history 
captured by different diagnostic interviews (ie, MINI vs SCID) will 
also be standardized to capture important diagnostic features (eg, 
BD subtype; psychosis subtype; # prior episodes; comorbidities) on 
the same scale. Measures of everyday functioning, including inter‐
personal, occupational and independent living status will be incor‐
porated to provide a benchmark of how cognitive capacity translates 
to some of the most important aspects of a patient's life. Again, as 
different groups use unique tests to assess these constructs, we will 
devise metrics to allow for inclusion of data from multiple different 
scales.
Data analyses will begin by asking the simple questions first, 
including but not limited to: (a) As a group, how do BD patients 
compare with healthy controls on cognitive outcomes (case vs 
control)? (b) How does current mood symptom severity influ‐
ence cognition in BD? (c) Do BD I patients differ from BD II pa‐
tients on cognitive measures? (d) Do BD patients with a history 
Site Investigator name(s) Location
Brigham and Women’s Hospital/
Harvard
Katherine Burdick USA
Copenhagen University Hospital Kamilla Miskowiak, Lars Kessing Denmark
University of Otago Richard Porter New Zealand
University of Melbourne Tamsyn Van Rheenen Australia
King’s College London Allan Young UK
National Center for Neurology and 
Psychiatry
Tomiki Sumiyoshi Japan
University of Barcelona Eduard Vieta, Anabel Martinez‐Aran Spain
University of British Columbia Yatham Lakshmi, Ivan Torres Canada
University of Sao Paulo Beny Lafer Brazil
Newcastle University Peter Gallagher UK
McLean Hospital Kathryn Eve Lewandowski USA
University of Michigan Melvin McInnis USA
Queens University Christopher Bowie, Philip Harvey, 
Ann Pulver
Canada
Vanderbilt University Neil Woodward, Stephan Heckers USA
University of California at San Diego Lisa Eyler USA
TA B L E  1   Initial sites for ICONIC‐BD
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of psychosis fare worse than those without such a history? (e) 
How does duration of illness influence cognitive performance, 
and is this relative to episode load? (f) What role do comorbid‐
ities (substance use disorders, anxiety disorders) play in cogni‐
tive outcome? (g) How can we best address the confounder of 
medication effects on cognitive performance? The list of possible 
questions to be addressed is extensive and ICONIC‐BD will pro‐
vide a rich dataset with unmatched statistical power to begin to 
answer many of them.
While clinical outcome measures related to social, personal, 
and vocational functioning form the core of the collaboration, it 
is imperative to consider the course of cognitive capacity as the 
individual with BD ages. Since cognitive decline with age is an in‐
evitable component of humanity, are individuals with BD affected 
sooner? How can the consequences of such decline be mitigated in 
the bipolar population? To study and answer such questions, it is 
necessary to study a large population over time, in many cultures 
and locations.
While these questions may seem straightforward, they have 
not yet been unambiguously answered in any single dataset. 
Moreover, with the power of collaboration, we will be able to con‐
duct more sophisticated analyses to answer questions that can bet‐
ter address the multi‐factorial nature of cognition in BD. Analyses 
of mediators and moderators of cognitive outcome can address 
interactions among these key illness features. Classification meth‐
ods (eg, clustering, latent profiles) can be used to empirically parse 
cognitive heterogeneity, establishing potentially meaningful new 
“subtypes” in the largest study to date. Addressing these complex 
questions is key to understanding what causes cognitive impair‐
ment in a large subset of patients with BD. This is the first (and a 
critical) step in determining how best to treat and ultimately pre‐
vent this disabling symptom, which would have direct and immedi‐
ate effects on quality of life for many patients with BD.
Beyond the initial set‐up of this data base, ICONIC‐BD will 
also serve as a platform for additional collaborative projects (eg, 
subcommittees for those sites that have DNA, or those with neu‐
roimaging data, or those interested in establishing a network for 
treatment trials targeting cognition). We hope that this dataset 
and interconnected worldwide network will also lead to addi‐
tional funding for this very important and understudied area of 
research.
The overarching goal of this initiative is the creation of the world's 
largest, publicly available database on cognition in BD. This will pro‐
mote work that could not be done by any single investigator/labo‐
ratory. The massive success of other similar consortia in psychiatry 
(Psychiatric Genomics Consortium [PGC]; Enhancing NeuroImaging 
Genetics through Meta‐analysis [ENIGMA]; Cognitive Genomics 
Consortium [COGENT], among others) provides strong support for 
scientific advances through the kind of collaboration and data shar‐
ing that is planned in ICONIC‐BD. Moreover, collaborative initiatives 
such as ICONIC‐BD may foster agreement across research groups, 
not only in analyzing the available data, but in generating new data 
using common instruments and methodologies moving forward.
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